Stockscreener 앱 받기
7.52
2.87%
0.21
시간 외 거래:
7.52
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In - Seeking Alpha
Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases - Yahoo Finance
Insider Stock Buying Of Nuvectis Pharma Delivers Return On US$2.19m Investment - simplywall.st
Nuvectis Pharma Approves Proposals at Annual Meeting - TipRanks
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Sold by Two Sigma Investments LP - Defense World
Millennium Management LLC Reduces Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Investment Analysis - news.stocktradersdaily.com
Squarepoint Ops LLC Invests $103,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Bought by Northern Trust Corp - Defense World
(NVCT) On The My Stocks Page - news.stocktradersdaily.com
Cubist Systematic Strategies LLC Invests $34,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
When (NVCT) Moves Investors should Listen - news.stocktradersdaily.com
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewswire
Nuvectis pharma investor Charles Mosseri Marlio buys $247k in stock By Investing.com - Investing.com India
Q2 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright - Defense World
Roth Capital Forecasts Stronger Earnings for Nuvectis Pharma - Defense World
Nuvectis Pharma Launches New $60M Stock Offering Program - TipRanks
Nuvectis Pharma launches public stock offering - MSN
(NVCT) Investment Report - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Nuvectis Pharma Reports Q1 2025 Progress and Financials - TipRanks
Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year - TipRanks
Nuvectis (NVCT) Advances Clinical Programs with Promising Updates | NVCT Stock News - GuruFocus
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Nuvectis Pharma’s (NVCT) “Buy” Rating Reiterated at HC Wainwright - Defense World
Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies - TipRanks
Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 - Insider Monkey
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting - The Manila Times
Nuvectis Pharma, Inc. Announces Positive Phase 1a Data for NXP900 Demonstrating Robust Pharmacodynamic Responses and Acceptable Safety Profile - Nasdaq
Breakthrough: Nuvectis NXP900 Cancer Drug Achieves 90% Target Inhibition in Phase 1 Trial - Stock Titan
Nuvectis Pharma (NASDAQ:NVCT) Trading 5.3% Higher – Here’s What Happened - Defense World
(NVCT) Trading Signals - news.stocktradersdaily.com
Is Nuvectis Pharma Inc (NASDAQ: NVCT) A Good Pick For New Investors Now? - Stocksregister
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis pharma investor acquires $1.2 million in stock - MSN
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$36m last week; individual investors who hold 48% profited and so did insiders - simplywall.st
SCHD ETF News, 4/14/2025 - The Globe and Mail
Top 5 Small-cap Pharma Stocks in 2025 - Investing News Network
When the Price of (NVCT) Talks, People Listen - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World
Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target - MarketScreener
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference - MarketScreener
CEO ClipsOrvana Minerals: Expanding Gold, Silver & Copper Production Across Key Global Regions - The Globe and Mail
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
New Cancer Treatment Breakthrough: NXP900 Data Showcase at Major AACR Conference - Stock Titan
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Large Decline in Short Interest - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Laidlaw - Defense World
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Laidlaw starts Nuvectis Pharma stock with Buy, $19 target By Investing.com - Investing.com Canada
1.45%
0.86%
자본화:
|
볼륨(24시간):